Understanding peripheral arterial disease in the current era (++)

Understanding peripheral arterial disease in the current era Prof Christian-Alexander Behrendt, MDa,b Send email to behrendt@hamburg.de ∙ Prof Lars Norgren, PhDc ∙ Chalotte W Nicolajsen, PhDd ∙ Prof Janet T Powell, PhDe,* ∙ Prof Vivienne Chuter, PhDf ∙ Prem Chand Gupta, MSg ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00846-9/fulltext?dgcid=raven_jbs_etoc_feature_lancet NHS campaigners target Palantir Talha Burki https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01982-3/abstract?dgcid=raven_jbs_etoc_feature_lancet

Peripheral arterial disease: counting what matters The Lancet (+...)

Peripheral arterial disease: counting what matters The Lancet https://www.thelancet.com/journals/lancet/issue/vol408no10562/PIIS0140-6736(26)X2037-2

Read our latest conference content (+++++) (++) (++) Explore our content from the 2026 EASD Annual Meeting

ARTICLES Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial Free with registration https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01861-1/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_easd26&_hsenc=p2ANqtz-_r1Dmvb7T-E6QtshsIsW_CF-gpEDtPM0nd7tEh6wtepp-UJebJLlezRpUgVVN0I-JdE33FaTm84Qla75a7gPl1XhXZLg&_hsmi=442052802&utm_content=442052802&utm_source=hs_email Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial Free with registration until Oct 10th, 2026 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01865-9/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_easd26&_hsenc=p2ANqtz-_tj1EfwbL31mOjpkeFyeq-r7Zbw5dkI4tFeTtOZo4cE11wQ4S3V5PzlNVA3JI5veyYVKmSdP6XDl9NBHu1jSPaTXagsw&_hsmi=442052802&utm_content=442052802&utm_source=hs_email Trends in prevalence of type 2 diabetes and intermediate hyperglycaemia in Mauritius from 1987 to 2021 based on results from the oral glucose tolerance test: a repeated cross-sectional study Free with registration https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00127-0/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_easd26&_hsenc=p2ANqtz-9lnDzZF490fd7NABqnn-dLxRO5a_y3xXF7zFJZGMS8faWrYLXu5lkiZQvKpfhbdQXMDar2_2f85NCCvNpDKSFqHtr1tA&_hsmi=442052802&utm_content=442052802&utm_source=hs_email Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo controlled, phase 2 trial Free with registration until Oct 10th, 2026 https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00213-5/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_easd26&_hsenc=p2ANqtz--VKv3L8iBDSnC4WfebATUSs7xctpnZH4P4ZW1Kf8ivB2b4hzFRzfEdVl8P0ZWHLIXRsVjlhPyGucOkuCO_LJlMTsDKHg&_hsmi=442052802&utm_content=442052802&utm_source=hs_email Dual-hormone fully closed-loop therapy versus multiple daily insulin injections or hybrid closed-loop therapy in adults with type 1 diabetes: a multicentre, open-label, randomised controlled trial Open Access https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00284-X/fulltext?dgcid=hubspot_email_conferencealerts_easd26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-9F6tq5Gvtjgttekewkos0dhcgEE_2fhNtJker3x4bEd2xhRnfxo2g-og1tutRZuzDuZ23yqagNi17Uwv8u8F1zs465lQ&_hsmi=442052802&utm_content=442052802&utm_source=hs_email COMMENTS What Mauritius teaches us about diabetes surveillance Free with registration https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00159-2/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_easd26&_hsenc=p2ANqtz-_8vmmq6DaGgIIQCBZRSzE9FfR9G7Z7ZjDV1PeYlqyySmv17IK_X7Kw5oMNcKdOmrQ9Nf5Szyj8pDNsGeu2yAPsJCbHCQ&_hsmi=442052802&utm_content=442052802&utm_source=hs_email Petrelintide and the evolving role of amylin agonism in obesity Free with registration until Oct 10th, 2026 https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00216-0/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_easd26&_hsenc=p2ANqtz-_U6SBfWQ0GJpTSVbdynSHR7lj6p0bb9I_uteZWAIkypWZMtrYXuwEDyahURX-ZfyFJ-1UPV_0mw5dym2pjlCh99FwOnQ&_hsmi=442052802&utm_content=442052802&utm_source=hs_email SERIES Global barriers to GLP-1 receptor agonist treatment in women: access, safety, and equity Free with registration https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038(26)00228-1/fulltext?dgcid=hubspot_email_conferencealerts_easd26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz--GwJFUOqmay51XTKIUOf-zqGmJvQpNSyhpEQfbgiAKn5IkyV6DaIC9daiOVBGBqdra5XxUO56WQCSLDq3vZmAeNe15Bw&_hsmi=442052802&utm_content=442052802&utm_source=hs_email Preconception, pregnancy, and postnatal use of GLP-1 receptor agonist-based therapies in women with type 1, type 2, or gestational diabetes: a systematic review, meta analysis, and international expert consensus statement Free with registration https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038(26)00266-9/fulltext?dgcid=hubspot_email_conferencealerts_easd26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-9Q0X2zvcEYIbAjz1RFWmXd6LRO3O6l9-GhrcKRhWSCBfYZBSbKOY1zFs7S-SUxzQRlh9PWrcCKESRlGtP4nqmk_saepA&_hsmi=442052802&utm_content=442052802&utm_source=hs_email

Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial Prof Sheraz Yaqub, MD PhDa,b Send email to sheraz.yaqub@medisin.uio.no ∙ Morten Valberg, PhDc ∙ Bjørn Atle Bjørnbeth, MD PhDa ∙ Jon-Helge Angelsen, MD PhDd,e ∙ Kristoffer Watten Brudvik, MD PhDa ∙ Ina Andrassy Eilertsen, PhDf ∙ et al.

Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial Prof Sheraz Yaqub, MD PhDa,b Send email to sheraz.yaqub@medisin.uio.no ∙ Morten Valberg, PhDc ∙ Bjørn Atle Bjørnbeth, MD PhDa ∙ Jon-Helge Angelsen, MD PhDd,e ∙ Kristoffer Watten Brudvik, MD PhDa ∙ Ina Andrassy Eilertsen, PhDf ∙ et al. https://www.thelancet.com/journals/langas/article/PIIS2468-1253(26)00260-8/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ihpba26&_hsenc=p2ANqtz-8dpguG_cBBSA_NrbdyonXHBGmFr4osFo9lOq9RKriYu6U80R_1teTApjRFgVKd2oNEAiPxK_XfhJjrHNxXwhbvvJ3HDw&_hsmi=442102189&utm_source=hs_email

Whole genome sequencing for Klebsiella pneumoniae in the Tunisian antimicrobial resistance surveillance system: micro-costing, pragmatic cost-effectiveness, and budget impact evaluation

Whole genome sequencing for Klebsiella pneumoniae in the Tunisian antimicrobial resistance surveillance system: micro-costing, pragmatic cost-effectiveness, and budget impact evaluation Dana Itania Send email to dana.itani@alumni.lshtm.ac.uk ∙ Kasim Allelb,c ∙ Sanaa Farjanid,k ∙ Hanen Smaouie ∙ Meriam Zribif ∙ Lamia Thabetg ∙ et al. https://www.thelancet.com/journals/laneme/article/PIIS3050-5054(26)00005-0/fulltext?dgcid=hubspot_email_conferencealerts_gmi16&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-_F4pzVHPhNJPBhxMDosRxh5zyeuYmYSgVktHlyZqMbqWbyYSKaftmKQMOrEiDcTdkLOvdoo-8E6i-qM9YISTGsPizTvg&_hsmi=442103080&utm_source=hs_email

Optimizing the Adult NF1 Journey: A Primary Care and Nonspecialist Guide to Surveillance Authors: Eric Legius, MD, PhD; Anna Berghoff, MD, PhD; Victor-Felix Mautner, MD, PhD; Ignacio Blanco, MD, PhD

https://www.medscape.org/viewarticle/optimizing-adult-nf1-journey-primary-care-and-nonspecialist-2026a1000zq3?page=1

The Lung Cancer Landscape: Covering Key Advances in NSCLC and SCLC Authors: Heather Wakelee, MD, FASCO; Christina S. Baik, MD, MPH; Misty D. Shields, MD, PhD

https://www.medscape.org/viewarticle/lung-cancer-landscape-covering-key-advances-nsclc-and-sclc-2026a1000zw1?page=1